Summary

Global Nontuberculous Mycobacterium Treatment Market is valued approximately USD XX billion in 2020 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2021-2027. Nontuberculous mycobacterial lung disease is a serious infection caused by bacteria. These bacteria are common in the environment and cause lung damage. the bacteria can exist in water and soil particles that are in the air. Growing prevalence of chronic disease and rising aging population are key drivers for the growth of Nontuberculous Mycobacterium Treatment market. For instance, according to World Health Organization (WHO)- Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death globally, COPD caused 3.23 million deaths in the year 2019. Over 80% of all deaths caused in low- and middle-income countries. Also, as per The Office of Disease Prevention and Health Promotion (ODPHP) USA, as of 2020 more than 25 million people are suffering from asthma in the United States. Approximately 14.8 million adults are diagnosed with COPD, and about 12 million people have not yet been diagnosed also, annual health care expenditures for asthma, estimated at USD 20.7 billion. Also, with the increasing number of patient suffering from lung disease and surging healthcare infrastructure, the adoption & demand for Nontuberculous Mycobacterium Treatment is likely to increase the market growth during the forecast period. However, high cost of Nontuberculous Mycobacterium Treatment impedes the growth of the market over the forecast period of 2021-2027.

The key regions considered for the global Nontuberculous Mycobacterium Treatment market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the leading/significant region across the world in terms of market share owing to increasing nontuberculous mycobacterium infection and rising research and development in the region. Whereas, Europe is anticipated to exhibit highest growth rate / CAGR over the forecast period 2021-2027. Factors such as rising healthcare spending in the region would create lucrative growth prospects for the Nontuberculous Mycobacterium Treatment market across Asia-Pacific region.

Major market player included in this report are:
Insmed Incorporated
RedHill Biopharma,
Novoteris,
Savara,
Beyond Air
Kadmon.
Atara Bio.
Tercica.
JCR Pharmaceuticals.
BioMarin.
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Drug Type:
Clarithromycin
Azithromycin
Rifampin
Rifabutin
Ethambutol
Streptomycin
Amikacin.
By End Use Industries:
Hospitals Pharmacies
Private clinics
Drug stores and retail pharmacy
E-commerce
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019
Base year – 2020
Forecast period – 2021 to 2027

Target Audience of the Global Nontuberculous Mycobacterium Treatment Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors

ページTOPに戻る

Table of Contents

Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2027 (USD Billion)
1.2.1. Nontuberculous Mycobacterium Treatment Market, by Region, 2019-2027 (USD Billion)
1.2.2. Nontuberculous Mycobacterium Treatment Market, by Drug Type, 2019-2027 (USD Billion)
1.2.3. Nontuberculous Mycobacterium Treatment Market, by End Use Industries, 2019-2027 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Nontuberculous Mycobacterium Treatment Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Nontuberculous Mycobacterium Treatment Market Dynamics
3.1. Nontuberculous Mycobacterium Treatment Market Impact Analysis (2019-2027)
3.1.1. Market Drivers
3.1.1.1. Growing number of chronic diseases.
3.1.1.2. Rising Aging population.
3.1.2. Market Challenges
3.1.2.1. High Treatment Cost.
3.1.3. Market Opportunities
3.1.3.1. Rising prevalence of lung disease.
3.1.3.2. Surging health care industry.
Chapter 4. Global Nontuberculous Mycobacterium Treatment Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model (2018-2027)
4.2. PEST Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.3. Investment Adoption Model
4.4. Analyst Recommendation & Conclusion
4.5. Top investment opportunity
4.6. Top winning strategies
Chapter 5. Risk Assessment: COVID-19 Impact
5.1.1. Assessment of the overall impact of COVID-19 on the industry
5.1.2. Pre COVID-19 and post COVID-19 market scenario
Chapter 6. Global Nontuberculous Mycobacterium Treatment Market, by Drug Type
6.1. Market Snapshot
6.2. Global Nontuberculous Mycobacterium Treatment Market by Drug Type, Performance - Potential Analysis
6.3. Global Nontuberculous Mycobacterium Treatment Market Estimates & Forecasts by Drug Type 2018-2027 (USD Billion)
6.4. Nontuberculous Mycobacterium Treatment Market, Sub Segment Analysis
6.4.1. Clarithromycin
6.4.2. Azithromycin
6.4.3. Rifampin
6.4.4. Rifabutin
6.4.5. Ethambutol
6.4.6. Streptomycin
6.4.7. Amikacin.

Chapter 7. Global Nontuberculous Mycobacterium Treatment Market, by End Use Industries
7.1. Market Snapshot
7.2. Global Nontuberculous Mycobacterium Treatment Market by End Use Industries, Performance - Potential Analysis
7.3. Global Nontuberculous Mycobacterium Treatment Market Estimates & Forecasts by End Use Industries 2018-2027 (USD Billion)
7.4. Nontuberculous Mycobacterium Treatment Market, Sub Segment Analysis
7.4.1. Hospitals Pharmacies
7.4.2. Private clinics
7.4.3. Drug stores and retail pharmacy
7.4.4. E-commerce

Chapter 8. Global Nontuberculous Mycobacterium Treatment Market, Regional Analysis
8.1. Nontuberculous Mycobacterium Treatment Market, Regional Market Snapshot
8.2. North America Nontuberculous Mycobacterium Treatment Market
8.2.1. U.S. Nontuberculous Mycobacterium Treatment Market
8.2.1.1. Drug Type breakdown estimates & forecasts, 2018-2027
8.2.1.2. End Use Industries breakdown estimates & forecasts, 2018-2027
8.2.2. Canada Nontuberculous Mycobacterium Treatment Market
8.3. Europe Nontuberculous Mycobacterium Treatment Market Snapshot
8.3.1. U.K. Nontuberculous Mycobacterium Treatment Market
8.3.2. Germany Nontuberculous Mycobacterium Treatment Market
8.3.3. France Nontuberculous Mycobacterium Treatment Market
8.3.4. Spain Nontuberculous Mycobacterium Treatment Market
8.3.5. Italy Nontuberculous Mycobacterium Treatment Market
8.3.6. Rest of Europe Nontuberculous Mycobacterium Treatment Market
8.4. Asia-Pacific Nontuberculous Mycobacterium Treatment Market Snapshot
8.4.1. China Nontuberculous Mycobacterium Treatment Market
8.4.2. India Nontuberculous Mycobacterium Treatment Market
8.4.3. Japan Nontuberculous Mycobacterium Treatment Market
8.4.4. Australia Nontuberculous Mycobacterium Treatment Market
8.4.5. South Korea Nontuberculous Mycobacterium Treatment Market
8.4.6. Rest of Asia Pacific Nontuberculous Mycobacterium Treatment Market
8.5. Latin America Nontuberculous Mycobacterium Treatment Market Snapshot
8.5.1. Brazil Nontuberculous Mycobacterium Treatment Market
8.5.2. Mexico Nontuberculous Mycobacterium Treatment Market
8.6. Rest of The World Nontuberculous Mycobacterium Treatment Market

Chapter 9. Competitive Intelligence
9.1. Top Market Strategies
9.2. Company Profiles
9.2.1. Insmed Incorporated
9.2.1.1. Key Information
9.2.1.2. Overview
9.2.1.3. Financial (Subject to Data Availability)
9.2.1.4. Product Summary
9.2.1.5. Recent Developments
9.2.2. RedHill Biopharma,
9.2.3. Novoteris,
9.2.4. Savara,
9.2.5. Beyond Air
9.2.6. Kadmon.
9.2.7. Atara Bio.
9.2.8. Tercica.
9.2.9. JCR Pharmaceuticals.
9.2.10. BioMarin.

Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes
10.3. Research Assumption